Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients

NCT04942054 is registered in ClinicalTrials.gov with Sun Pharma Advanced Research Company Limited as lead sponsor.

NCT NCT04942054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04942054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Determine Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of SCO-120 in Hormone Receptor Positive, HER-2 Negative Advanced Breast Cancer Patients
Lead sponsor
Sun Pharma Advanced Research Company Limited
Phase
Phase 1
Overall status
Terminated
Start date
May 20, 2022
Completion date
February 28, 2023
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, her2-negative breast cancer, hormone receptor-positive breast cancer